AROPAX Paroxetine (as hydrochloride hemihydrate) oral liquid bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

paroxetine hydrochloride hemihydrate, Quantity: 2.276 mg/mL (Equivalent: paroxetine, Qty 2 mg/mL)

Available from:

Aspen Pharmacare Australia Pty Ltd

Pharmaceutical form:

Oral Liquid, suspension

Composition:

Excipient Ingredients: polacrilin potassium; dispersible cellulose; propylene glycol; glycerol; sorbitol solution (70 per cent) (crystallising); methyl hydroxybenzoate; propyl hydroxybenzoate; sodium citrate dihydrate; citric acid; saccharin sodium; sunset yellow FCF; purified water; Flavour; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; PEG-4 stearate

Administration route:

Oral

Units in package:

150mL

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

AROPAX is indicated for treatment of major depression and for the prevention of relapse of depressive symptoms; Obsessive Compulsive Disorder and for the prevention of relapse of OCD; Panic Disorder and for the prevention of relapse of Panic Disorder; Social Anxiety Disorder/Social Phobia; Generalised Anxiety Disorder; and Posttraumatic Stress Disorder.

Product summary:

Visual Identification: Bright orange fairly viscous suspension having an odour of oranges and free from foreign matter.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

1999-03-29